
April 1 (Reuters) - Medical device maker Becton Dickinson BDX.N has begun discussions to sell its life sciences division, valued at $21 billion, and is in talks with competitors such as Thermo Fisher Scientific TMO.N and Danaher DHR.N, the Financial Times reported on Tuesday.